Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat in Primary Aldosteronism (BaxPA)
NCT07007793Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of baxdrostat in primary hyperaldosteronism (PA), sponsored by AstraZeneca. Started Aug 2025; status: active, not recruiting.
02
Drugs
baxdrostat
03
Conditions
primary hyperaldosteronism (PA)
Beyond the preview
Go deeper on NCT07007793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007793.